肝细胞癌
计算生物学
转化研究
生物
体外
疾病
癌症
药物发现
基础研究
癌症研究
生物信息学
医学
计算机科学
病理
生物技术
遗传学
图书馆学
作者
Letícia Cardoso Valente,Gabriel Bacil Prata,Luana Riechelmann-Casarin,Giullia Cavichiolli Barbosa,Luı́s Fernando Barbisan,Guilherme Ribeiro Romualdo
出处
期刊:Life Sciences
[Elsevier]
日期:2024-08-01
卷期号:351: 122781-122781
标识
DOI:10.1016/j.lfs.2024.122781
摘要
The hepatocellular carcinoma (HCC) features a remarkable epidemiological burden, ranking as the third most lethal cancer worldwide. As the HCC-related molecular and cellular complexity unfolds as the disease progresses, the use of a myriad of in vitro models available is mandatory in translational preclinical research setups. In this review paper, we will compile cutting-edge information on the in vitro bioassays for HCC research, (A) emphasizing their morphological and molecular parallels with human HCC; (B) delineating the advantages and limitations of their application; and (C) offering perspectives on their prospective applications. While bidimensional (2D) (co) culture setups provide a rapid low-cost strategy for metabolism and drug screening investigations, tridimensional (3D) (co) culture bioassays - including patient-derived protocols as organoids and precision cut slices - surpass some of the 2D strategies limitations, mimicking the complex microarchitecture and cellular and non-cellular microenvironment observed in human HCC. 3D models have become invaluable tools to unveil HCC pathophysiology and targeted therapy. In both setups, the recapitulation of HCC in different etiologies/backgrounds (i.e., viral, fibrosis, and fatty liver) may be considered as a fundamental guide for obtaining translational findings. Therefore, a "multimodel" approach - encompassing the advantages of different in vitro bioassays - is encouraged to circumvent "model-biased" outcomes in preclinical HCC research.
科研通智能强力驱动
Strongly Powered by AbleSci AI